San Jose, Calif.-based C8 MediSensors received European CE Mark approval to launch its optical glucose monitoring system for diabetic patients.
The new non-invasive continuous glucose monitor features light spectroscopy that measures blood glucose levels without the need for frequent finger pricks.
"C8 MediSensors was co-founded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease," CEO Paul Zygielbaum said in prepared remarks. "CE Mark approval is a landmark step for this unique technology. Our team is hugely excited to be working to make nCGM and optical glucose monitor system available throughout Europe."
Studies show that continuous glucose monitoring can improve glycemic control and help reduce a diabetic patient’s risk of suffering hypoglycemia, according to the press release.
The company, which GE Healthcare (NYSE:GE) last December invested an undisclosed amount into, said the system could send glucose readings wirelessly to the user’s smartphone, providing a continuous picture of glucose dynamics throughout the day.
In clinical studies, the C8 MediSensors monitor showed accuracy comparable to earlier versions of invasive CGMs, but with less pain and less risk of infection, according to the press release.